Regional amino acid distribution in relation to function in insulin hypoglycaemia

Area of Science:

• Neuroscience
• Biochemistry

Background:

• Hypoglycaemic encephalopathy is a severe neurological condition.
• Amino acid neurotransmitters play critical roles in brain function.
• Understanding regional changes in amino acids during hypoglycaemia is crucial for comprehending brain injury mechanisms.

Purpose of the Study:

• To investigate the dynamic changes in specific amino acids during the development of hypoglycaemic encephalopathy.
• To identify brain regions most vulnerable to amino acid depletion under hypoglycaemic conditions.
• To correlate amino acid alterations with the onset of neurological symptoms and convulsions.

Main Methods:

• Measurement of glutamate, aspartate, gamma-aminobutyric acid (GABA), and glutamine using a sensitive double-labelling technique.
• Analysis of amino acid levels in whole brain and specific regions (cerebral cortex, striatum, hippocampus, medulla-pons) of rats.
• Induction of hypoglycaemia via insulin administration in fasted rats, with measurements taken at various developmental stages.

Main Results:

• No significant changes in whole brain glutamate, GABA, or glutamine were observed up to the onset of convulsions.
• Cerebral cortex showed a reduction in GABA levels (to 65% of normal) prior to neurological symptoms.
• Striatum and hippocampus exhibited marked decreases in glutamate and glutamine at symptom onset, alongside a significant increase in aspartate in the cerebral cortex of convulsing animals.
• Selective net loss of amino acids occurred in the cerebral cortex and striatum before the onset of insulin-hypoglycaemic convulsions.

Conclusions:

• Amino acid alterations in hypoglycaemic encephalopathy are region-specific and precede overt neurological symptoms.
• The cerebral cortex, striatum, and hippocampus are particularly vulnerable to amino acid disturbances during hypoglycaemia.
• GABA reduction in the cerebral cortex may serve as an early indicator of impending neurological dysfunction in hypoglycaemia.